Clinical Pharmacokinetics

, Volume 14, Issue 1, pp 35–51

Clinical Pharmacokinetics of Amantadine Hydrochloride

  • Fred Y. Aoki
  • Daniel S. Sitar
Review Article

Summary

Amantadine is a drug with diverse uses ranging from prevention of influenza A illness to the treatment of patients with Parkinson’s disease. It is available only in oral formulations from which it is well absorbed and widely distributed, little drug being present in the circulation. Apparent volume of distribution is inversely related to dose over the therapeutic range and accounts in part for a noteworthy logarithmic increase in plasma concentration as a function of dose. Elimination is primarily by renal clearance by both glomerular filtration and tubular secretion.

Amantadine accumulates in patients with renal dysfunction. Hence, doses must be reduced in such patients to avoid toxicity. Interactions with other drugs appear uncommon.

Relationships have been demonstrated between amantadine therapeutic effects and plasma concentrations in different study cohorts, but not in individual patients. Dose schedules have been suggested for individuals in whom amantadine kinetics are different from healthy subjects. However, these schedules are controversial in their choice of target concentrations and in being untested as to predictive value.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Alvan G, Kugelberg U, Sundqvist A, Tomson T. Amantadinin-toxikation vid njurinsufficiens. Lakartidningen 77: 3650, 1980PubMedGoogle Scholar
  2. Aoki FY, Sitar DS. Amantadine kinetics in healthy elderly men: implications for influenza prevention. Clinical Pharmacology and Therapeutics 37: 137–144, 1985PubMedCrossRefGoogle Scholar
  3. Aoki FY, Sitar DS. Amantadine toxicity during influenza A prophylaxis. Correspondence. Archives of Internal Medicine 147: 1189, 1987aPubMedCrossRefGoogle Scholar
  4. Aoki FY, Sitar DS. Effects of chronic amantadine hydrochloride ingestion on its and paracetamol pharmacokinetics in young adults. Submitted for publication, 1987bGoogle Scholar
  5. Aoki FY, Sitar DS, Ogilvie RI. Amantadine kinetics in healthy young subjects after long-term dosing. Clinical Pharmacology and Therapeutics 26: 727–736, 1979Google Scholar
  6. Aoki FY, Stiver HG, Sitar DS, Boudreault A, Ogilvie RI. Prophylactic amantadine dose and plasma concentration-effect relationships in healthy adults. Clinical Pharmacology and Therapeutics 37: 128–136, 1985PubMedCrossRefGoogle Scholar
  7. Armbruster KFW, Rahn AC, Ing TS, Halper IS, Dyama JH, et al. Amantadine toxicity in a patient with renal insufficiency. Nephron 13: 183–186, 1974PubMedCrossRefGoogle Scholar
  8. Atkinson WL, Arden NH, Patriarca PA, Leslie N, Lui K-J, et al. Amantadine prophylaxis during an institutional outbreak of type A (HINI) influenza. Archives of Internal Medicine 146: 1751–1756, 1986PubMedCrossRefGoogle Scholar
  9. Belanger PM, Grech-Belanger D. Gas-liquid chromatographic determination of plasma and urinary levels of amantadine in man. Journal of Chromatography 228: 327–332, 1982PubMedCrossRefGoogle Scholar
  10. Belanger PM, Grech-Belanger O, Labadie R. Depression of hepatic microsomal enzyme systems by amantadine hydrochloride in the rat. Journal of Pharmacology and Experimental Therapeutics 211: 485–490, 1979PubMedGoogle Scholar
  11. Biandrate P, Tognoni G, Belvedere G, Frigerio A, Rizzo M, et al. A gas chromatographic method for the determination of amantadine in human plasma. Journal of Chromatography 74: 31–34, 1972PubMedCrossRefGoogle Scholar
  12. Bleidner WE, Harmon JB, Hewes WE, Lynes TE, Hermann EC. Absorption, distribution and excretion of amantadine hydrochloride. Journal of Pharmacology and Experimental Therapeutics 150: 484–490, 1965PubMedGoogle Scholar
  13. Blye E, Lorch J, Cortell S. Extracorporeal therapy in the treatment of intoxication. American Journal of Kidney Diseases 3: 321–338, 1984PubMedGoogle Scholar
  14. Borison RL. Amantadine-induced psychosis in a geriatric patient with renal disease. American Journal of Psychiatry 136: 111–112, 1979PubMedGoogle Scholar
  15. Bryson YJ, Monahan C, Pollack M, Shields WD. A prospective double-blind study of side effects associated with the administration of amantadine for influenza A virus prophylaxis. Journal of Infectious Diseases 141: 543–547, 1982CrossRefGoogle Scholar
  16. Centers for Disease Control, Department of Health and Human Sciences. Recommendations for prevention and control of influenza. Annals of Internal Medicine 105: 399–404, 1986Google Scholar
  17. Chopra YM, Dandiya PC. Potentiation of anticatatonic effect of antidepressants by amantadine. Indian Journal of Medical Research 66: 142–149, 1977PubMedGoogle Scholar
  18. Crispens CG. Handbook on the laboratory mouse, pp. 82–90, Charles C. Thomas, Springfield, 1975Google Scholar
  19. Daugirdas JT, Ing IL, Cheng PJ, Wu MJ, Klawans HL, et al. Binding of amantadine to red blood cells. Therapeutic Drug Monitoring 6: 399–401, 1984PubMedCrossRefGoogle Scholar
  20. DiMascio A, Bernardo DL, Greenblatt DJ, Marder JE. A controlled trial of amantadine in drug-induced extrapyramidal disorders. Archives of General Psychiatry 33: 599–602, 1976PubMedCrossRefGoogle Scholar
  21. Dolin R, Reichman RC, Madore HP, Maynard R, Linton PN, et al. A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. New England Journal of Medicine 307: 580–584, 1982PubMedCrossRefGoogle Scholar
  22. Dourmashkin R, Tyrrell DAJ. Electron microscope observations on the entry of influenza virus into susceptible cells. Journal of General Virology 24: 129–141, 1974PubMedCrossRefGoogle Scholar
  23. Fahn S, Craddock G, Kumin G. Acute toxic psychosis from suicidal over-dosage of amantadine. Archives of Neurology 25: 45–48, 1971PubMedCrossRefGoogle Scholar
  24. Farnebo LO, Fuxe K, Goldstein M, Manberg B, Ungerstedt U. Dopamine and noradrenaline releasing action of amantadine in the central and peripheral nervous system: a possible mode of action in Parkinson’s disease. European Journal of Pharmacology 16: 27–38, 1971PubMedCrossRefGoogle Scholar
  25. Fasano VA, Urciuoli R, Broggi G. Prime osservazioni sull’uso dell’Amantadina per via endovenosa e delle associazione dell’Amantadina per via orale con farmaci anticolinergici e con levo-dopa nel trattamento della malattia di Parkinson. Minerva Medica (Torino) 61: 2895–2903, 1970Google Scholar
  26. Fenton RJ, Bessell C, Spilling CR, Potter CW. The effects of peroral or local aerosol administration of 1-aminoadamantane hydrochloride (amantadine hydrochloride) on influenza infections of the ferret. Journal of Antimicrobial Chemotherapy 3: 463–472, 1977PubMedCrossRefGoogle Scholar
  27. Finklea JF, Hennessy AV, Davenport FM. A field trial of amantadine prophylaxis in naturally occurring acute respiratory illness. American Journal of Epidemiology 65: 403–412, 1967Google Scholar
  28. Geuens HF, Stephens RL. Influence of the pH of the urine on the rate of excretion of 1-adamantanamine. 5th International Congress of Chemotherapy, Vienna, June 26–July 1, 1967, pp. 703–713, Verlag der Wiener Medizinischen Akademie, Vienna, 1967Google Scholar
  29. Gill MJ, Sitar DS, Aoki FY. Initial pharmacokinetic evaluation of amantadine hydrochloride administered intravenously to young healthy volunteers. Abstract. Clinical and Investigative Medicine 5: 5B, 1982Google Scholar
  30. Greenblatt DJ, Dimasco A, Harmatz JS, Bernardo DL, Marder JE. Pharmacokinetics and clinical effects of amantadine in drug-induced extra-pyramidal symptoms. Journal of Clinical Pharmacology 17: 704–708, 1977PubMedGoogle Scholar
  31. Grelak RP, Clark R, Stump JM, Vernier VG. Amantadine-dopamine interaction: possible mode of action in Parkinsonism. Science 169: 203–204, 1970PubMedCrossRefGoogle Scholar
  32. Hayden FG, Gwaltney Jr JM, Van De Castle RL, Adams KF, Giordani B. Comparative toxicity of amantadine hydrochloride and rimantadine hydrochloride in healthy adults. Antimicrobial Agents and Chemotherapy 19: 226–233, 1981PubMedCrossRefGoogle Scholar
  33. Hayden FG, Hall WJ, Douglas Jr RG, Speers DM. Amantadine aerosols in normal volunteers: pharmacology and safety testing. Antimicrobial Agents and Chemotherapy 16: 644–650, 1979PubMedCrossRefGoogle Scholar
  34. Hayden FG, Hoffman HE, Spyker DA. Differences in side effects of amantadine hydrochloride and rimantadine hydrochloride relate to differences in pharmacokinetics. Antimicrobial Agents and Chemotherapy 23: 458–464, 1983PubMedCrossRefGoogle Scholar
  35. Hayden FG, Minocha A, Spyker DA, Hoffman HE. Comparative single-dose pharmacokinetics of amantadine hydrochloride and rimantadine hydrochloride in young and elderly adults. Antimicrobial Agents and Chemotherapy 28: 216–221, 1985PubMedCrossRefGoogle Scholar
  36. Horadam VW, Sharp JG, Smilack JD, McAnalley BH, Garriott JC, et al. Pharmacokinetics of amantadine hydrochloride in subjects with normal and impaired renal function. Annals of Internal Medicine 94: 454–458, 1981PubMedGoogle Scholar
  37. Ing TS, Cheng PJ, Wu MJ, Daugirdas JT, Soung LS. Plasma protein-binding of amantadine in maintenance hemodialysis patients. International Journal of Artificial Organs 7: 235, 1984PubMedGoogle Scholar
  38. Ing TS, Daugirdas JT, Soung LS, Klawans HL, Mahurkar SD, et al. Toxic effects of amantadine in patients with renal failure. Canadian Medical Association Journal 120: 695–698, 1979PubMedGoogle Scholar
  39. Jackson GG, Stanley ED, Muldoon RL. Chemoprophylaxis of viral respiratory diseases. 1st International Conference on Vaccines against Viral and Rickettsial Diseases of Man, p. 595, Scientific publication no. 147, Pan American World Health Organization, Washington, DC, 1967Google Scholar
  40. Johnson RG, Carty SE, Scarpa A. Accumulation of amantadine by isolated chromaffin granules. Biochemical Pharmacology 30: 763–769, 1981PubMedCrossRefGoogle Scholar
  41. Kelly JT, Zimmerman RL, Abuzzahab FS, Schiele BC. A double-blind study of amantadine hydrochloride versus benztropine mesylate in drug-induced Parkinsonism. Pharmacology 12: 65–73, 1974PubMedCrossRefGoogle Scholar
  42. Knight V, Bloom K, Wilson SZ, Wilson RK. Amantadine aerosol in humans. Antimicrobial Agents and Chemotherapy 16: 572–578, 1979PubMedCrossRefGoogle Scholar
  43. Koppel C, Tenczer J. A revision of the metabolic disposition of amantadine. Biomedical Mass Spectrometry 12: 499–501, 1985PubMedCrossRefGoogle Scholar
  44. Leeming JK. Amantadine hydrochloride and the elderly. Lancet 1: 313–314, 1969Google Scholar
  45. Liu P, Cheng PJ, Ing TS, Daugirdas JT, Jeevanandhan R, et al. In vitro binding of amantadine to plasma proteins. Clinical Neuropharmacology 7: 149–151, 1984PubMedCrossRefGoogle Scholar
  46. Merrick EM, Schmitt PP. A controlled study of the clinical effects of amantadine hydrochloride (Symmetrel®). Current Therapeutic Research 15: 552–558, 1973PubMedGoogle Scholar
  47. Messiha FS. Antagonism of ethanol-evoked responses by amantadine: a possible clinical application. Pharmacology Biochemistry and Behavior 8: 573–577, 1978CrossRefGoogle Scholar
  48. Mindham RHS, Gaind R, Anstee BH, Rimmer L. Comparison of amantadine, orphenadrine, and placebo in the control of phenothiazine-induced Parkinsonism. Psychological Medicine 2: 406–413, 1972PubMedCrossRefGoogle Scholar
  49. Montanari C, Ferrari P, Bavazzano A. Urinary excretion of amantadine by the elderly. European Journal of Clinical Pharmacology 8: 349–351, 1975PubMedCrossRefGoogle Scholar
  50. Monto AS, Gunn RA, Bandyk MG, King CL. Prevention of Russian influenza by amantadine. Journal of the American Medical Association 241: 1003–1007, 1979PubMedCrossRefGoogle Scholar
  51. O’Malley K, Stevenson IH, Turnbull MJ. Amantadine and drug metabolism. Lancet 1: 685, 1972PubMedCrossRefGoogle Scholar
  52. Oxford JS, Galbraith A. Antiviral activity of amantadine: a review of laboratory and clinical data. Pharmacology and Therapeutics 11: 181–262, 1980PubMedCrossRefGoogle Scholar
  53. Pacifici GM, Nardini M, Ferrari P, Latini R, Fieschi C, et al. Effects of amantadine on drug-induced Parkinsonism: relationship between plasma levels and effect. British Journal of Clinical Pharmacology 3: 883–889, 1976PubMedCrossRefGoogle Scholar
  54. Parkes D. Amantadine. Advances in Drug Research 8: 8–11, 1974Google Scholar
  55. Parkes JD, Zilha KJ, Marsden P, Baxter RCH, Knill-Jones RP. Amantadine dosage in treatment of Parkinson’s disease. Lancet 1: 1130–1133, 1970PubMedCrossRefGoogle Scholar
  56. Peacocke J, Eadie J. Influenza. Canada Diseases Weekly Report 6: 242–243, 1980Google Scholar
  57. Perrin DD, Hawkins I. The dissociation constant of the 1-amino-adamantane cation. Experientia 28: 880, 1972CrossRefGoogle Scholar
  58. Postma JU, Van Tilburg W. Visual hallucinations and delirium during treatment with amantadine (Symmetrel). Journal of the American Geriatrics Society 23: 212–215, 1975PubMedGoogle Scholar
  59. Quilligan Jr JJ, Hirayama M, Baernstein Jr MD. The suppression of A2 influenza in children by the chemoprophylactic use of amantadine. Journal of Pediatrics 69: 572–575, 1966PubMedCrossRefGoogle Scholar
  60. Renkin EM, Robinson RR. Glomerular filtration. New England Journal of Medicine 290: 785–792, 1974PubMedCrossRefGoogle Scholar
  61. Richman DD, Yazaki P, Hostetier KY. The intracellular distribution and antiviral activity of amantadine. Virology 112: 81–90, 1981PubMedCrossRefGoogle Scholar
  62. Rizzo M, Biandrate P, Tognoni G, Morselli PL. Amantadine in depression: relationship between behavioural effects and plasma levels. European Journal of Clinical Pharmacology 5: 226–228, 1973CrossRefGoogle Scholar
  63. Schwab RS, England Jr AC, Poskanzer DC, Young RR. Amantadine in the treatment of Parkinson’s disease. Journal of the American Medical Association 208: 1168–1170, 1969PubMedCrossRefGoogle Scholar
  64. Sioufi A, Pommier F. Gas chromatographic determination of amantadine hydrochloride (Symmetrel) in human plasma and urine. Journal of Chromatography 183: 33–39, 1980PubMedCrossRefGoogle Scholar
  65. Skehel JJ, Hay AJ, Armstrong JA. On the mechanism of inhibition of influenza virus replication by amantadine hydrochloride. Journal of General Virology 38: 97–110, 1978PubMedCrossRefGoogle Scholar
  66. Smith CB, Purcell RH, Chancock RM. Effect of amantadine hydrochloride on parainfluenza type 1 virus infections in adult volunteers. American Review of Respiratory Diseases 95: 689–690, 1967Google Scholar
  67. Smorodintsev AA, Zlydnikov DM, Kiseleva AM, Romanov JA, Kazantsev AP, et al. Evaluation of amantadine in artificially induced A2 and B influenza. Journal of the American Medical Association 213: 1448–1454, 1970PubMedCrossRefGoogle Scholar
  68. Solovyov VN, Tolmacheva NS. Therapeutic effect of amantadine aerosol in experimental influenza infection of white mice. Acta Virology 11: 482–487, 1967Google Scholar
  69. Soung L-S, Ing TS, Daugirdas JT, Wu M-J, Gandhi VC, et al. Amantadine hydrochloride pharmacokinetics in hemodialysis patients. Annals of Internal Medicine 93: 46–49, 1980PubMedGoogle Scholar
  70. Stumph MJ, Noall MW, Knight V. Gas-chromatographic determination of amantadine in human urine. Clinical Chemistry 26: 295–296, 1980PubMedGoogle Scholar
  71. Taylor Dickinson PC, Chang TW, Weinstein L. Effects of amantadine on influenza B and measles virus infection in children. In Proceedings of the 6th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, Philadelphia, Oct 26–28, 1966. pp. 521–526, 1967Google Scholar
  72. Tilles JG. Antiviral agents. Annual Review of Pharmacology 14: 469–489, 1974CrossRefGoogle Scholar
  73. Tyrrell DAJ, Bynoe ML, Hoorn B. Studies on the antiviral activity of 1-adamantanamine. British Journal of Experimental Pathology 46: 370–375, 1965PubMedGoogle Scholar
  74. Uchiyama M, Shibuya M. Distribution and excretion of 3H-amantadine HCl. Chemical and Pharmaceutical Bulletin 17: 841–843, 1969CrossRefGoogle Scholar
  75. Vernier VG, Harmon JB, Stump JM, Lynes TE, Marvel JP, et al. The toxicologic and pharmacologic properties of amantadine hydrochloride. Toxicology and Applied Pharmacology 15: 642–665, 1969PubMedCrossRefGoogle Scholar
  76. Walker JS, Stephen EL, Spertzel RO. Small particle aerosols of antiviral compounds in treatment of type A influenza pneumonia in mice. Journal of Infectious Diseases 133 (Suppl.): A140–144, 1976PubMedCrossRefGoogle Scholar
  77. Wesemann VW, Schollmeyer JD, Sturm G. Gaschromatographische und massenspektrometrische Untersuchungen uber harnpflichtige Metabolite von Adamantanaminen. Arzneimittel-Forschung 27: 1471–1477, 1977PubMedGoogle Scholar
  78. Wilson TW, Rajput AH. Amantadine-Dyazide interaction. Canadian Medical Association Journal 129: 974–975, 1983PubMedGoogle Scholar
  79. Wright PF, Khan KT, Oxman MN, Schwachman H. Evaluation of the safety of amantadine HCI and the role of respiratory viral infections in children with cystic fibrosis. Journal of Infectious Diseases 134: 144–149, 1976PubMedCrossRefGoogle Scholar
  80. Wu MJ, Ing TS, Soung LS, Daugirdas JT, Hano JE, Gandhi VC. Amantadine hydrochloride pharmacokinetics in patients with impaired renal function. Clinical Nephrology 17: 19–23, 1982PubMedGoogle Scholar

Copyright information

© ADIS Press Limited 1988

Authors and Affiliations

  • Fred Y. Aoki
    • 1
  • Daniel S. Sitar
    • 1
  1. 1.Sections of Clinical Pharmacology and Infectious Diseases, Faculty of MedicineUniversity of ManitobaWinnipegCanada
  2. 2.Room 510, Basic Medical Sciences Building Department of Medical MicrobiologyUniversity of ManitobaWinnipegCanada

Personalised recommendations